Global $35 Billion Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics" report to their offering.

The urological cancers market, including bladder, kidney, prostate and testicular cancer, will increase from $17.9 billion in 2015 to $35.9 billion by 2022, at a substantial compound annual growth rate of 10.39%, according to the publisher.

This latest report states that this strong market growth will be driven by the predicted emergence of targeted therapies for bladder cancer and increasing prostate and kidney cancer prevalence.

The development and approval of immune checkpoint inhibitors will lower the associated toxicity of urological cancer therapies and increase their usage in typically poor-performance patients, who have a reduced functional status. Targeted treatment administration will increase patients' overall survival and enable more rounds of chemotherapy to be given.

It is predicted that two new urological cancer drugs for the treatment of bladder cancer - Roche's atezolizumab and AstraZeneca's durvalumab - will achieve blockbuster status by 2022. The former is anticipated to achieve revenue of $2.5 billion in 2022, following approval from late 2016, and its uptake will be driven by a lack of targeted therapies for bladder cancer, along with increasing prevalence and clinician familiarity.

The latter is anticipated to generate $1.2 billion in 2022, following its expected approval in 2017. It is expected to be one of an increasing number of cancer immunotherapies for bladder cancer, providing less toxic options for treatment of the malignancy, and enabling administration to patients with poorer performance statuses.

Although drugs such as atezolizumab and durvalumab are not expected to surpass the revenues generated by the currently marketed drugs Opdivo or Xtandi due to a competitive market landscape, their approval and uptake will cause shifts in market dynamics.

This report provides analysis of the global urological cancer space across the seven major countries of the US, France, Germany, Italy, Spain, the UK, and Japan. It includes annualized market data from 2015 and forecast to 2022.

Key Topics Covered:

1 Tables & Figures

2 Introduction

2.1 Disease Cluster Introduction

2.2 Symptoms

2.3 Etiology and Pathophysiology

2.4 Co-morbidities and Complications

2.5 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates

2.6 Treatment

3 Key Marketed Products

3.1 Overview

3.2 Zytiga (abiraterone acetate)

3.3 Xtandi (enzalutamide)

3.4 Sutent (sunitinib malate)

3.5 Votrient (pazopanib hydrochloride)

3.6 Inlyta (axitinib)

3.7 Jevtana (cabazitaxel)

3.8 Xofigo (radium Ra 223 dichloride)

3.9 Provenge (sipuleucel-T)

3.10 Opdivo (nivolumab) - Bristol-Myers Squibb

3.11 Conclusion

4 Pipeline Landscape Assessment

4.1 Overview

4.2 Pipeline Development Landscape

4.3 Molecular Targets in the Pipeline

4.4 Clinical Trials

4.5 Conclusion

4.6 Assessment of Key Pipeline Products

4.7 Conclusion

5 Multi-Scenario Market Forecast to 2022

5.1 Overall Market Size

5.2 Generic Penetration

5.3 Revenue Forecast by Molecular Target

6 Company Analysis and Positioning

6.1 Revenue and Market Share Analysis by Company

6.1.1 Pfizer - Will a Patent Cliff Be Avoided Following the Expiries of Sutent and Inlyta?

6.1.2 Novartis - How Will Upcoming Patent Expiries Affect Urological Cancer Revenues?

6.1.3 Johnson & Johnson - How Will Zytiga Perform in an Increasingly Competitive Prostate Cancer Treatment Market?

6.1.4 Astellas - What Will Become of Xtandi?

6.1.5 AstraZeneca - Will Sales Revenues Increase over the Forecast Period?

6.1.6 Bristol-Myers Squibb - How Will Cancer Immunotherapies Affect Urological Cancers?

6.2 Company Landscape

6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations

7.1 Licensing Deals

7.2 Co-development Deals

8 Appendix

For more information visit http://www.researchandmarkets.com/research/xrkj98/global_urological

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology Drugs , Biopharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology Drugs , Biopharmaceuticals